Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data.

[1]  G. Montepiedra,et al.  Isoniazid Preventive Therapy in HIV-Infected Pregnant and Postpartum Women. , 2019, The New England journal of medicine.

[2]  Natalie S Blencowe,et al.  RoB 2: a revised tool for assessing risk of bias in randomised trials , 2019, BMJ.

[3]  R. Chaisson,et al.  One Month of Rifapentine plus Isoniazid to Prevent HIV‐Related Tuberculosis , 2019, The New England journal of medicine.

[4]  D. Dowdy,et al.  Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  R. Salamon,et al.  Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial. , 2017, The Lancet. Global health.

[6]  H. Zar,et al.  Isoniazid for preventing tuberculosis in HIV‐infected children , 2017, The Cochrane database of systematic reviews.

[7]  K. Maitland,et al.  Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa , 2017, The New England journal of medicine.

[8]  R. Riley,et al.  Meta‐analysis using individual participant data: one‐stage and two‐stage approaches, and why they may differ , 2016, Statistics in medicine.

[9]  R. Chaisson,et al.  Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons , 2016, AIDS.

[10]  M. Raviglione,et al.  The WHO's new End TB Strategy in the post-2015 era of the Sustainable Development Goals , 2016, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[11]  M. Bonten,et al.  Isoniazid Prophylactic Therapy for the Prevention of Tuberculosis in HIV Infected Adults: A Systematic Review and Meta-Analysis of Randomized Trials , 2015, PloS one.

[12]  R. Salamon,et al.  A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. , 2015, The New England journal of medicine.

[13]  Paul T. von Hippel,et al.  The heterogeneity statistic I 2 can be biased in small meta-analyses , 2015 .

[14]  Paul T. von Hippel,et al.  Estimates of heterogeneity (I2) can be biased in small meta-analyses , 2014, 1410.2296.

[15]  G. Maartens,et al.  Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial , 2014, The Lancet.

[16]  G. Rutherford,et al.  Early initiation of antiretroviral therapy in HIV-infected adults and adolescents: a systematic review , 2014, AIDS.

[17]  R. Chaisson,et al.  Antiretroviral Therapy for Prevention of Tuberculosis in Adults with HIV: A Systematic Review and Meta-Analysis , 2012, PLoS medicine.

[18]  R. Chaisson,et al.  New regimens to prevent tuberculosis in adults with HIV infection. , 2011, The New England journal of medicine.

[19]  F. Aversa,et al.  Regression modeling of competing risk using R: an in depth guide for clinicians , 2010, Bone Marrow Transplantation.

[20]  Michele Tarsilla.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, Journal of MultiDisciplinary Evaluation.

[21]  J. Ioannidis,et al.  The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, BMJ : British Medical Journal.

[22]  R. Chaisson,et al.  Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort , 2009, AIDS.

[23]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[24]  THE WORLD HEALTH ORGANIZATION , 1954 .

[25]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[26]  J. Volmink,et al.  Treatment of latent tuberculosis infection in HIV infected persons. , 2004, The Cochrane database of systematic reviews.

[27]  Joint United Nations Programme on HIV/AIDS (UNAIDS)-WHO. Revised recommendations for the selection and use of HIV antibody tests. , 1997, Releve epidemiologique hebdomadaire.